Administration of two uroselective alpha-adrenoblockers in pharmacological treatment of acute urinary retention in patients with prostatic adenoma


Cite item

Full Text

Abstract

Acute urinary retention in males is often caused by infravesical obstruction due to enlargement of the prostatic gland. Recently it was found that alpha-adrenoblockers promote recovery of physiological voiding in patients with benign prostatic hyperplasia. In our study urinary bladder draining with urethral catheter in 136 patients with acute urinary retention was immediately followed by simultaneous administration of two alpha1-adrenoblockers - alfuzosine (10 mg once a day) (dalfaz CP) and tamsulosine (0.4 mg once a day) (omnik okas). The control group of 96 patients received monotherapy with alfuzosine. Physiological voiding recovered in 42.7% patients on alfuzosine monotherapy and in 64% patients on alfuzosine+tamsulosine.

About the authors

P I Rasner

D Yu Pushkar

References

  1. Kaplan S. A., Wein A. J., Staskin D. R. et al. Urinary retention and post-void residual urine in men: Separating truth from tradition. J. Urol. (Baltimore) 2008; 180: 47-54.
  2. Abarbanel J., Marus E. L. Impaired detrusor contractility in community-dwelling elderly presenting with lower urinary tract symptoms. Urology 2007; 69: 436.
  3. Drake M. J., Nixon P. M., Crew J. P. Drug-induced bladder and urinary disorders. Incidence, prevention and management. Drug Saf. 1998; 19: 45.
  4. Cespedes R. D. Treatment options for outlet obstruction following antiincontinence surgery in females. Techn. Urol. 2001; 7: 118.
  5. Gleave J. R., MacFarlane R. Prognosis for recovery of bladder function following lumbar central disc prolapse. Br. J. Neurosurg. 1990; 4: 205.
  6. Thomas A. W., Cannon A., Bartlett E. et al. The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. Br. J. Urol. Int. 2004; 93: 745.
  7. Verhamme K. M., Dieleman J. P., van Wijk M. A. et al. Low incidence of acute urinary retention in the general male population: the triumph project. Eur. Urol. 2005; 47: 494.
  8. Meigs J. B., Barry M. J., Giovannucci E. et al. Incidence rates and risk factors for acute urinary retention: the Health Professionals Followup Study. J. Urol. (Baltimore) 1999; 162: 376.
  9. Vega Ch. Management of urinary retention reviewed. Am. Fam. Physician 2008; 77: 643-650.
  10. Marberger M. J., Andersen J. T., Nickel J. C. et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Eur. Urol. 2000; 38: 563-568.
  11. Giovannucci E., Stampfer M. J., Kawachi I. Incidence rate and risk factors for acute urinary retention: the Health Professionals Follow-up Study. J. Urol. (Baltimore) 1998; 159 (5): 103.
  12. Marberger M. J. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998; 51: 677.
  13. Roehrborn C. G., Bruskewitz R., Nickel G. C. et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group. Eur. Urol. 2000; 37: 528.
  14. Roberts R. O., Lieber M. M., Jacobson D. J. et al. Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. Mayo Clin. Proc. 2005; 80: 759.
  15. Jacobsen S. J., Jacobson D. J., Girman C. J. et al. Natural history of prostatism: risk factors for acute urinary retention. J. Urol. (Baltimore) 1997; 158 (2): 481-487.
  16. Emberton M., Fitzpatrick J. M. The Reten-World survey of the management of acute urinary retention: preliminary results. Br. J. Urol. Int. 2008; 101 (suppl. 3): 27-32.
  17. Meigs J. B., Barry M. J., Giovannucci E. et al. Incidence rates and risk factors for acute urinary retention: the Health Professionals Follow-up Study. J. Urol. (Baltimore) 1999; 162: 376.
  18. Cathcart P., van der Meulen J., Armitage J., Emberton M. Incidence of primary and recurrent acute urinary retention between 1998 and 2003 in England. J. Urol. (Baltimore) 2006; 176: 200.
  19. Manikandan R., Srirangam S. J., O'Reilly P. H., Collins G. N. Management of acute urinary retention secondary to benign prostatic hyperplasia in the UK: a national survey. Br. J. Urol. Int. 2004; 93 (1): 84-88.
  20. Choong S., Emberton M. Acute urinary retention. Br. J. Urol. Int. 2000; 85: 186-201.
  21. McNeill S. A. Does acute urinary retention respond to alpha-blockers alone? Eur. Urol. 2001; 39 (suppl. 6): 7-12.
  22. Loh S. Y., Chin C. M. A demographic profile of patients undergoing transurethral resection of the prostate for benign prostate hyperplasia and presenting in acute urinary retention. Br. J. Urol. Int. 2002; 89 (6): 531-533.
  23. McNeill S. A. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction. Eur. Urol. 2004; 45 (3): 325-332.
  24. Перепанова Т. С., Камалов А. А., Синюхин В. Н. и др. Доксазозин (Кардура) при острой задержке мочеиспускания, обусловленной доброкачественной гиперплазией простаты. Урология 2001; 3: 18-20.
  25. Kumar V., Marr C., Bhuvangiri A., Irwin P. A prospective study of conservatively managed acute urinary retention: prostate size matters. Br. J. Urol. Int. 2000; 86 (7): 816-819.
  26. Вишневский А. Е., Пушкарь Д. Ю., Сухоруков В. С. Особенности энергетического метаболизма детрузора у больных доброкачественной гиперплазией предстательной железы. Клин. фармакол. и тер. 2003; 5: 66-69.
  27. Лоран О. Б., Вишневский Е. Л., Вишневский А. Е. Лечение расстройств мочеиспускания у больных доброкачественной гиперплазией простаты α-адреноблокаторами. М.; 1998.
  28. Shapiro E., Hartanto V., Lepor H. Quantifying the smooth muscle content of prostate using double-immunoenzymatic staining and color assisted image analysis. J. Urol. (Baltimore) 1992; 147: 1167-1170.
  29. Пушкарь Д. Ю., Раснер П. И. Опыт применения альфузозина в лечении острой задержки мочи у больных доброкачественной гиперплазией предстательной железы. Фарматека 2004; 16 (93): 43-47.
  30. Luis Prieto, Jesüs Romero, Cristóbal López et al. Efficacy of Doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urol. Int. 2008; 81: 66-71.
  31. Bae J. H., Park H. S., Khae Hawn Kim et al. Single intermittent catheterization as a modality of trial without catheterization in patients with acute urinary retention due to benign prostatic obstruction. J. Urol. (Baltimore) 2009; 181 (4): 651.
  32. Kim H. L., Kim J. C., Benson D. A. et al. Results of treatment with tamsulosin in men with acute urinary retention. Techn. Urol. 2001; 7 (4): 256-260.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies